We are live on
!
Find out more
PHS
PFM Health Sciences Portfolio holdings
AUM
$1.17B
1-Year Est. Return
92.19%
This Fund
S&P 500
This Quarter
Est. Return
+25.19%
1 Year Est. Return
+92.19%
3 Year Est. Return
+240.57%
5 Year Est. Return
+377.11%
10 Year Est. Return
+3,179.38%
AUM
$4.52B
AUM Growth
+$762M
(+20%)
Cap. Flow
-$364M
Cap. Flow
% of AUM
-8.05%
Top 10 Holdings %
Top 10 Hldgs %
32.69%
Holding
126
New
33
Increased
18
Reduced
34
Closed
36
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Stryker
SYK
|
+$104M |
| 2 |
WCG
Wellcare Health Plans, Inc.
WCG
|
+$86M |
| 3 |
AGN
Allergan plc
AGN
|
+$83.3M |
| 4 |
Pfizer
PFE
|
+$80.2M |
| 5 |
Puma Biotechnology
PBYI
|
+$79.5M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ONCE
Spark Therapeutics, Inc. Common Stock
ONCE
|
+$145M |
| 2 |
Abbott
ABT
|
+$82.8M |
| 3 |
GoDaddy
GDDY
|
+$79.9M |
| 4 |
AERI
Aerie Pharmaceuticals
AERI
|
+$68.4M |
| 5 |
Blackrock
BLK
|
+$65.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 58.29% |
| 2 | Miscellaneous | 22.3% |
| 3 | Technology | 11.18% |
| 4 | Communication Services | 3.96% |
| 5 | Consumer Discretionary | 3.1% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
Invesco QQQ Trust
QQQ
$489B
| $366M | 8.08% |
+2,035,700
| New | +$345M |
|
2
CALL
Qualcomm
QCOM
$180B
| $187M | 4.13% |
+3,278,600
| New | +$177M |
|
|
ARNA
3
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $146M | 3.23% |
3,255,230
+240,558
| +8% | +$11M |
|
4
Zimmer Biomet
ZBH
$18.7B
| $121M | 2.68% |
979,783
+281,105
| +40% | +$31.9M |
|
|
5
Pfizer
PFE
$162B
| $120M | 2.66% |
2,986,083
+2,002,189
| +203% | +$80.2M |
|
|
6
Stryker
SYK
$116B
| $114M | 2.53% |
+579,444
| New | +$104M |
|
7
UnitedHealth
UNH
$356B
| $112M | 2.47% |
451,689
+210,804
| +88% | +$53.8M |
|
8
Penumbra
PEN
$12.7B
| $107M | 2.36% |
727,057
-175,841
| -19% | -$25.1M |
|
9
CALL
Humana
HUM
$48.2B
| $105M | 2.31% |
+393,100
| New | +$113M |
|
|
10
Puma Biotechnology
PBYI
$493M
| $101M | 2.23% |
+2,603,920
| New | +$79.5M |
|
11
Elevance Health
ELV
$88.4B
| $99.4M | 2.2% |
346,397
-105,024
| -23% | -$30.4M |
|
|
12
Humana
HUM
$48.2B
| $97M | 2.14% |
364,473
-43,620
| -11% | -$12.6M |
|
|
WCG
13
DELISTED
Wellcare Health Plans, Inc.
WCG
| $89.8M | 1.98% |
+332,834
| New | +$86M |
|
14
ICU Medical
ICUI
$4.19B
| $89.7M | 1.98% |
374,860
+199,102
| +113% | +$47.7M |
|
15
Microchip Technology
MCHP
$40.3B
| $85.2M | 1.88% |
2,053,642
-11,342
| -0.5% | -$470K |
|
|
WCG
16
CALL
DELISTED
Wellcare Health Plans, Inc.
WCG
| $84.8M | 1.87% |
+314,500
| New | +$81.2M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $84.2M | 1.86% |
+574,837
| New | +$83.3M |
|
|
MYOK
18
DELISTED
MyoKardia, Inc. Common Stock
MYOK
| $83.3M | 1.84% |
1,601,307
+63,176
| +4% | +$2.91M |
|
|
19
GoDaddy
GDDY
$12.8B
| $80.8M | 1.79% |
1,074,417
-1,136,391
| -51% | -$79.9M |
|
|
BOLD
20
DELISTED
Audentes Therapeutics, Inc
BOLD
| $79.2M | 1.75% |
2,030,481
-990,778
| -33% | -$28.4M |
|
21
CALL
State Street SPDR NYSE Technology ETF
XNTK
$2.01B
| $79.1M | 1.75% |
+2,666,000
| New | +$178M |
|
|
BPMC
22
DELISTED
Blueprint Medicines
BPMC
| $77.2M | 1.71% |
964,075
-506,361
| -34% | -$37.4M |
|
23
Thermo Fisher Scientific
TMO
$227B
| $77M | 1.7% |
281,436
+19,329
| +7% | +$4.81M |
|
24
Molina Healthcare
MOH
$10.5B
| $71.1M | 1.57% |
500,538
+151,379
| +43% | +$20.5M |
|
25
Edwards Lifesciences
EW
$51.8B
| $68.9M | 1.52% |
1,080,921
-541,560
| -33% | -$30.9M |
|
Similar funds
JC
PRS
MK
HCP
EC
M
CCM
VFP
PFM Health Sciences's Q1 2019 Portfolio in Review
As of Q1 2019, PFM Health Sciences held 126 positions worth $4.52B, up 20% from $3.76B the previous quarter. Its ten largest holdings account for 33% of the portfolio.
PFM Health Sciences withdrew a net $364M in Q1 2019, closing 36 positions and reducing 34 holdings. Its most notable exit was Abbott, an estimated $82.8M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 58% of assets, up from 57% a quarter earlier, followed by Miscellaneous and Technology.
Against the trend, PFM Health Sciences opened a new position in Stryker worth $114M.
- PFM Health Sciences's largest Q1 2019 buy was Stryker: 579,444 shares worth $114M.
- PFM Health Sciences added most to Pfizer in Q1 2019, an estimated $80.2M increase.
- PFM Health Sciences's biggest Q1 2019 reduction was Spark Therapeutics, Inc. Common Stock, cutting an estimated $145M.
- PFM Health Sciences fully exited Abbott in Q1 2019, selling an estimated $82.8M.
- PFM Health Sciences's ten largest holdings make up 33% of its $4.52B portfolio in Q1 2019.
- PFM Health Sciences opened 33 new positions and closed 36 in Q1 2019.
- PFM Health Sciences's portfolio value rose 20% quarter-over-quarter to $4.52B.
Based on PFM Health Sciences's 13F filing for Q1 2019, filed 15 May 2019.